Skip to main content
OpenTrials

Clinical trial condition

Fanconi Anemia, Complementation Group D1

Explore clinical trials studying Fanconi Anemia, Complementation Group D1. Study availability and eligibility vary by location and protocol.

27 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Fanconi Anemia, Complementation Group D1 trial results

Completed

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population

NCT02503436

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +16 more
Locations
  • Research Site Amberg, Germany
  • Research Site Aschaffenburg, Germany
  • Research Site Augsburg, Germany
  • Research Site Bad Homburg, Germany
View all 68 locations
View Trial Details
Completed

Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma

NCT02039388

Conditions
Adnexal Diseases, Carcinoma, Carcinoma in Situ, +20 more
Locations
  • Medical University Graz - Universitätsklinik f. Frauenheilkunde u. Geburtshilfe Graz, Austria
  • Kepler University Linz Linz, Austria
  • Medical University Vienna, Dptm. of Obstetrics & Gynaecology Vienna, Austria
  • Catholic University Leuven - Department of Obstetrics and Gynaecology Leuven, Belgium
View all 14 locations
View Trial Details
Completed

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

NCT04425200

Conditions
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fanconi Anemia, Complementation Group D1, +19 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Hirosaki University Hospital Hirosaki, Aomori, Japan
  • Jikei University Kashiwa Hospital Kashiwa, Chiba, Japan
View all 26 locations
View Trial Details
Completed

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

NCT00628251

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site San Francisco, California, United States
  • Research Site Boca Raton, Florida, United States
  • Research Site Boston, Massachusetts, United States
View all 24 locations
View Trial Details
Completed

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987

Conditions
Adnexal Diseases, Advanced or Recurrent Solid Tumors, Breast Diseases, +49 more
Locations
  • Scottsdale Healthcare Scottsdale, Arizona, United States
  • Virginia G. Piper Cancer Center Research Pharmacy Scottsdale, Arizona, United States
  • (IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center Los Angeles, California, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
View all 15 locations
View Trial Details

Related conditions